Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...

Replimune Group (NASDAQ: REPL) reported its Q3 earnings results on Tuesday, February 3, 2026 at 08:00 AM. Here's what investors need to know about the announcement. Replimune Group beat estimated ...

A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. The meeting was conducted with U.S. Food and Drug Administration (FDA) ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. 10 stocks we like better than Replimune Group › On Thursday, Replimune ...

WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...